| Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease. | |
| | |
MedLine Citation:
|
PMID: 18081729 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Patients with non-erosive reflux disease can experience reflux symptoms with similar frequency and severity as those with erosive reflux disease. Oesophageal motility and acid sensitivity are thought to influence symptom occurrence. AIM: To compare the effect of infused hydrochloric acid on oesophageal physiology in patients with non-erosive reflux disease and erosive reflux disease. METHODS: Twelve healthy controls and 39 patients with reflux disease [14 erosive reflux disease, 11 non-erosive reflux disease with normal (functional heartburn) and 14 non-erosive reflux disease with excess acid exposure] had hydrochloric acid and saline infused into distal and then proximal oesophagus. Oesophageal contraction amplitude, lower oesophageal sphincter pressure and pain intensity were documented at baseline and during each infusion. RESULTS: Patients with non-erosive reflux disease had higher pain sensitivity to acid than those with erosive reflux disease and controls. Proximal acid infusion caused greater pain than distal in patients with non-erosive reflux disease. Acid and saline sensitivity were more pronounced in patients with functional heartburn. Lower oesophageal sphincter pressure and oesophageal contraction amplitudes were lower in the erosive reflux disease and non-erosive reflux disease groups, but did not change during infusions. CONCLUSIONS: Patients with non-erosive reflux disease and, to a lesser extent, patients with erosive reflux disease, are sensitive to acid in the oesophagus, being more sensitive to proximal acid. Hypersensitivity is most marked in functional heartburn patients. This acid sensitivity is not associated with motility change. |
| | |
Authors:
|
N M Thoua; D Khoo; C Kalantzis; A V Emmanuel |
Related Documents
:
|
17136289 - Treatment of gastroesophageal reflux disease. 11082779 - Differential diagnosis of local defense mechanism diseases in ent. 17059509 - Review article: from 1906 to 2006--a century of major evolution of understanding of gas... 8578239 - Individualized acute treatment strategies for gastroesophageal reflux disease. 10780569 - Clinical epidemiology and natural history of gastroesophageal reflux disease. 9783769 - Air oesophagogram: a frequent, but not a specific sign of oesophageal involvement in co... 18289069 - Role of heme oxygenase-1 in vascular disease. 11189709 - Lyme disease. 12963569 - Adverse childhood experiences and self-reported liver disease: new insights into the ca... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2007-12-07 |
Journal Detail:
|
Title: Alimentary pharmacology & therapeutics Volume: 27 ISSN: 1365-2036 ISO Abbreviation: Aliment. Pharmacol. Ther. Publication Date: 2008 Mar |
Date Detail:
|
Created Date: 2008-01-29 Completed Date: 2008-03-31 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8707234 Medline TA: Aliment Pharmacol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 396-403 Citation Subset: IM |
Affiliation:
|
Physiology Unit, University College Hospital, London, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Case-Control Studies Esophageal Motility Disorders / physiopathology Esophagoscopy Female Gastroesophageal Reflux / metabolism* Heartburn / metabolism Humans Hydrochloric Acid / metabolism* Hydrogen-Ion Concentration Infusions, Parenteral Male Middle Aged Pain* Pain Measurement / methods Sensitivity and Specificity Sodium Chloride / metabolism |
| Chemical | |
Reg. No./Substance:
|
7647-01-0/Hydrochloric Acid; 7647-14-5/Sodium Chloride |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Serum retinol-binding protein 4 is not increased in obesity or obesity-associated type 2 diabetes me...
Next Document: The use of adalimumab in the management of refractory Crohn's disease.